Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”
Overview
Archive, CME credit no longer available
Release Date: March 26, 2009
Expiration Date: March 27, 2010
This activity consists of audio and visual recording of 8 live presentations. To receive CME credit, please read the overview and follow the link to the presentation.
To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.
Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.
Needs and Objectives
Upon completion of this activity, learners will be able to:
- Design antiretroviral strategies that consider current data on:
- HIV pathogenesis as it impacts clinical treatment
- Newly approved drugs and assays
- The interface between therapy and the biological aspect of prevention
- When to initiate therapy
- Manage cardiovascular disease in aging HIV-infected patients
- Explain adherence and resistance to HIV therapy
- Develop effective strategies for treating metabolic complications in HIV therapy
CME Credit
The International AIDS Society–USA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The International AIDS Society–USA designates this educational activity for a maximum of
5.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.
Intended Audience
This online CME activity is designed for physicians who are actively involved in HIV/AIDS care. Specifically, these activities have been designed for physicians who:
- Have a solid, working knowledge of HIV disease management
- Provide comprehensive or specialty care for at least 10 patients with HIV/AIDS or are involved in HIV/AIDS clinical trials or investigations
- Have completed at least 10 hours of CME in the area of HIV/AIDS medicine in the past 2 years
This activity is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care to people with HIV disease.
Course Faculty
Chairs
Gerald H. Friedland, MD
Professor of Medicine, Epidemiology,
and Public Health
Yale University School of Medicine
Director, AIDS Care Program
Yale-New Haven Hospital
New Haven, Connecticut
Paul A. Volberding, MD
Member, Board of Directors (Volunteer)
International AIDS Society–USA
Marvin Sleisenger Professor of Medicine
Vice-Chair, Department of Medicine
University of California San Francisco
Chief of Medical Service
San Francisco Veterans Affairs Medical Center
San Francisco, California
Speakers
David R. Bangsberg, MD, MPH
Lecturer on Medicine
Harvard Medical School
Senior Research Scientist
Massachusetts General Hospital
Boston, Massachusetts
Myron S. Cohen, MD
J. Herbert Bate Distinguished Professor of Medicine,
Microbiology and Public Health
Director, Division of Infectious Diseases
Director, UNC Center for Infectious Diseases
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Daniel Douek, MD, PhD
Bethesda, Maryland
Amy C. Justice, MD, PhD
Associate Professor of Medicine and Public Health
Yale University
Department of Internal Medicine
Section Chief, General Medicine
West Haven Veterans Affairs Healthcare System
West Haven, Connecticut
Paul E. Sax, MD
Associate Professor of Medicine
Harvard Medical School
Clinical Director, HIV Program and Division of Infectious Diseases
Brigham and Women’s Hospital
Boston, Massachusetts
David A. Wohl, MD
Associate Professor
Division of Infectious Diseases
AIDS Clinical Trials Unit
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Disclosure of Financial Affiliations
In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the International AIDS Society-USA requires all persons with control of content (ie; faculty, IAS-USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.
IAS-USA Board of Directors
Constance A. Benson, MD
Dr Benson has received research grants awarded to the University of California San Diego from Gilead Sciences, Inc. She has served on advisory boards for GlaxoSmithKline, Merck & Co, Inc, and Pfizer Inc, and chaired data and safety monitoring boards for Johnson & Johnson Research, Ltd (Australia) and Achillion Pharmaceuticals, Inc. (Updated 02/12/09)
Judith S. Currier, MD
Dr Currier has received research grants and research support from Merck & Co, Inc, Schering Plough Corp, Theratechnologies Inc, and Tibotec Therapeutics. She has served as a scientific advisor to Bristol-Myers Squibb, Merck & Co, Inc, and Tibotec Therapeutics and on a data and safety monitoring boards for Achillion Pharmaceuticals, Inc, and Koronis Pharmaceuticals. (Updated 02/05/09)
Carlos del Rio, MD
Dr del Rio has received research grants awarded to Emory University from GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, and Sanofi Pasteur. He served as a consultant or received honoraria from Bristol-Myers Squibb, Merck & Co, Inc, and Trinity Biotech Plc. (Updated 02/12/09)
Joel E. Gallant, MD, MPH
Dr Gallant has received grants and research support from Gilead Sciences, Inc, Merck & Co, Inc, Pfizer Inc, Roche Laboratories, and Tibotec Therapeutics. He has received honoraria from Abbott Laboratories, Gilead Sciences, Inc, GlaxoSmithKline, and Monogram Biosciences, Inc. He has served as a consultant to or was on the advisory boards for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, RAPID Pharmaceuticals, Inc, Schering-Plough Corp, and Tibotec Therapeutics. He is a member of data and safety monitoring boards for Abbott Laboratories, Gilead Sciences, Inc, Koronis Pharmaceuticals, and VIRxSYS Corp. (Updated 02/05/09)
Roy M. Gulick, MD, MPH
Dr Gulick has served as a consultant to Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pathway Pharmaceuticals Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, Schering-Plough Corp, Tibotec Therapeutics, and Virostatics. He also serves as Chair of a data and safety monitoring board for Koronis Pharmaceuticals. (Updated 02/06/09)
Donna M. Jacobsen
Ms Jacobsen had no relevant financial affiliations to disclose. (Updated 02/05/09)
Douglas D. Richman, MD
Dr Richman has served as a consultant to Anadys Pharmaceuticals, Inc, Biota, Bristol-Myers Squibb, Gilead Sciences, Inc, Idenex Pharmaceuticals, Merck & Co, Inc, Monogram Biosciences, Inc, Pfizer Inc, and Roche Laboratories. He was on the advisory board for Chimerix Inc. (Updated 02/09/09)
Michael S. Saag, MD
Dr Saag has received grants and research support from Achillion Pharmaceuticals, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Merck & Co, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, and Tibotec Therapeutics. He has served as a consultant to Ardea Biosciences, Inc, Avexa, Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Monogram Biosciences, Inc, Pain Therapeutics, Inc, Panacos Pharmaceuticals, Inc, Pfizer Inc, Progenics Pharmaceuticals, Inc, Roche Laboratories, Tibotec Therapeutics, Tobira Therapeutics, and Virco Lab, Inc. (Updated 02/05/09)
Robert T. Schooley, MD
Dr Schooley served as a consultant to Achillion Pharmaceuticals, Inc, Anadys Pharmaceuticals, Inc, Ardea Biosciences, Inc, Chimerix, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, iTherX, Inc, Koronis Pharmaceuticals, Merck & Co, Inc, Monogram Biosciences, Inc, Pfizer Inc, TaiMed Biologics, Tibotec Therapeutics, and Vertex Pharmaceuticals. He had stock options for Achillion Pharmaceuticals, Inc, and Monogram Biosciences, Inc. (Updated 02/13/09)
Paul A. Volberding, MD
Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, and Tobira Therapeutics and has been on an endpoint adjudication committee for Schering-Plough Corp for an ongoing clinical trial. He is a member of data safety and monitoring boards for Merck & Co, Inc, and TaiMed Biologics. He served as a consultant to Pfizer Inc and received an unrestricted educational grant from GlaxoSmithKline-Italy. (Updated 02/05/09)
Course Faculty and Staff
Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.
Dr Bangsberg had no relevant financial affiliations to disclose. (02/27/09)
Dr Cohen had no relevant financial affiliations to disclose. (02/20/09)
Dr Douek had no relevant financial affiliations to disclose. (02/16/09)
Dr Friedland received grants and research support from Boehringer Ingelheim Pharmaceuticals, Inc and Bristol-Myers Squibb. (02/16/09)
Dr Justice had no relevant financial affiliations to disclose. (02/24/09)
Dr Sax received grants and research support from GlaxoSmithKline, Merck & Co, Inc, and Tibotec Therapeutics. He served as a consultant to or contributed to CME program materials for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pfizer Inc, and Tibotec Therapeutics. (Updated 01/28/09)
Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Pfizer Inc, Schering-Plough Corp, and Tobira Therapeutics and has been on an endpoint adjudication committee for Schering-Plough Corp for an ongoing clinical trial. He is a member of data safety and monitoring boards for Merck & Co, Inc, and TaiMed Biologics. He served as a consultant to Pfizer Inc and received an unrestricted educational grant from GlaxoSmithKline-Italy. (Updated 02/05/09)
Dr Wohl received grant support from Merck & Co, Inc. He was a speaker for Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, and Tibotec Therapeutics. (Updated 02/16/09)
IAS–USA CME Staff
Ms Jacobsen has no relevant financial affiliations to disclose.
Grant Support
This Webcast activity is sponsored by the International AIDS Society–USA and funded by the International AIDS Society–USA.
Funding for the live activity, upon which this activity was based came from the following commercial companies:
Substantial Grants from:
Bristol-Myers Squibb
Tibotec Therapeutics
Merck & Co., Inc.
Gilead Sciences
Pfizer Inc
Discussion of Investigational or Unapproved Usage
This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the International AIDS Society–USA.
Contact Information
If you have any questions about this Web-based CME conference activity, please contact the International AIDS Society–USA:
International AIDS Society–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2010@iasusa.org
